Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $398,855.04 in Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Bryan Supran sold 1,758 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The stock was sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares in the company, valued at approximately $2,905,652.16. This represents a 12.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Alnylam Pharmaceuticals Stock Up 1.8%

Shares of NASDAQ:ALNY traded up $4.05 during trading on Tuesday, reaching $223.94. 1,353,733 shares of the stock traded hands, compared to its average volume of 1,449,769. The stock has a market cap of $29.97 billion, a P/E ratio of 41.62 and a beta of 0.28. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock has a 50-day moving average of $240.21 and a two-hundred day moving average of $279.65. Alnylam Pharmaceuticals, Inc. has a 52-week low of $197.81 and a 52-week high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a net margin of 15.26% and a return on equity of 84.93%. The company had revenue of $1.29 billion during the quarter, compared to analyst estimates of $1.32 billion. During the same period in the previous year, the business earned ($0.51) EPS. The firm’s revenue for the quarter was up 66.9% on a year-over-year basis. As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.71 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Wall Street Zen downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. Oppenheimer reduced their price objective on Alnylam Pharmaceuticals from $500.00 to $350.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Stifel Nicolaus decreased their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a research report on Friday, July 31st. Cantor Fitzgerald restated a “neutral” rating on shares of Alnylam Pharmaceuticals in a research note on Wednesday, September 30th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, August 31st. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $366.90.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in ALNY. Legal & General Group Plc purchased a new position in Alnylam Pharmaceuticals during the second quarter valued at approximately $278,321,000. Bank of New York Mellon Corp purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $148,128,000. Canada Pension Plan Investment Board purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $100,618,000. Korea Investment CORP purchased a new stake in shares of Alnylam Pharmaceuticals in the second quarter worth $74,553,000. Finally, Wellington Management Group LLP raised its position in shares of Alnylam Pharmaceuticals by 9.0% during the 2nd quarter. Wellington Management Group LLP now owns 2,110,407 shares of the biopharmaceutical company’s stock valued at $635,296,000 after purchasing an additional 174,482 shares during the period. Hedge funds and other institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi), a biological process that can selectively reduce the production of disease-causing proteins. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Alnylam’s commercial products include ONPATTRO (patisiran), an RNAi therapy for hereditary transthyretin-mediated amyloidosis with polyneuropathy; GIVLAARI (givosiran), for acute hepatic porphyria; OXLUMO (lumasiran), for primary hyperoxaluria type 1; and AMVUTTRA (vutrisiran), for transthyretin-mediated amyloidosis.